Lv51
940 积分 2023-02-28 加入
Do it
Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial
15天前
已完结
The present and future of bispecific antibodies for cancer therapy
17天前
已完结
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
18天前
已完结
Recent Advances in Immune-Based Therapies for Acute Myeloid Leukemia
25天前
已完结
CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn
1个月前
已完结
Industry Perspective on First‐in‐Human and Clinical Pharmacology Strategies to Support Clinical Development of T‐Cell Engaging Bispecific Antibodies for Cancer Therapy
1个月前
已完结
Clinical Pharmacology Strategies for Bispecific Antibody Development: Learnings from FDA‐Approved Bispecific Antibodies in Oncology
1个月前
已完结
Cytokine-mediated CAR T therapy resistance in AML
1个月前
已完结
Analysis of the CD33-related siglec family reveals that Siglec-9 is an endocytic receptor expressed on subsets of acute myeloid leukemia cells and absent from normal hematopoietic progenitors
1个月前
已完结
ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells
1个月前
已完结
皖公网安备34019202002308
